重组活化凝血因子 VII 持续输注的安全性、有效性及经验教训。重组活化凝血因子 VII 持续输注组。
Safety, efficacy and lessons from continuous infusion with rFVIIa. rFVIIa-CI Group.
作者信息
Schulman S
机构信息
Coagulation Unit, Karolinska Hospital, Stockholm, Sweden.
出版信息
Haemophilia. 1998 Jul;4(4):564-7. doi: 10.1046/j.1365-2516.1998.440564.x.
Abstract
Continuous infusion with coagulation factor concentrates has only been widely adopted during the last decade and with recombinant activated factor VII (rFVIIa) only during the last 2 years. Still the accumulated number of days on continuous infusion with this product amounts by now to more than one year, 35 patients and 26 surgical procedures. The experience is reviewed here and compared with data from the conventional bolus dose regimen.
摘要
凝血因子浓缩物的持续输注仅在过去十年中才被广泛采用，而重组活化因子VII（rFVIIa）的持续输注仅在过去两年中才得以应用。到目前为止，使用该产品持续输注的累计天数已超过一年，涉及35名患者和26例外科手术。本文回顾了相关经验，并与传统推注剂量方案的数据进行了比较。
Zotero 插件